IPO registrations (S-1, F-1) · Registrants
MAXCYTE, INC.
- SEC CIK
- 1287098 · filings on EDGAR ↗
- Former names
- MAXCYTE INC (2004–2008)
- Registration
- Form S-1, first filed 2021-07-09, last 2021-07-26; 1 initial registration, 1 amendment
- Outcome
- Final prospectus filed 2021-07-30; declared effective 2021-07-29
- Industry (SIC)
- Services-Commercial Physical & Biological Research 8731
- Incorporated in
- DE
- Business address
- 9713 KEY WEST AVENUE,, SUITE 400, Rockville, MD 20850
- EIN
- 52-2210438
- Ticker
- MXCT (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- MAXCYTE, INC. on the corporate pages
Offering terms
- Proposed price range
- $11.50–$13.50 per share (S-1/A filed 2021-07-26)
- Final price
- $13.00 per share, within the range (424B4 filed 2021-07-30, an initial public offering)
- Shares sold
- 13,500,000
- Gross proceeds
- $175,500,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol MXCT
- Lead underwriters
- Cowen (4,995,000 shares); Stifel (3,915,000 shares); William Blair (2,835,000 shares)
- Syndicate
- BTIG (1,080,000); Stephens (675,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: MAXCYTE, INC Fuzzy (name and state)
- Form 5500 plan sponsor: MAXCYTE, INC. EXACT (EIN (EXACT))
- Federal award recipient: MAXCYTE, INC. Fuzzy (name and state)
- Form D issuer: MAXCYTE, INC. EXACT (CIK (EXACT))
- SEC filer: MAXCYTE, INC. EXACT (CIK (EXACT))
- Person page: Stanley C Erck Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 5
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-07-09 | S-1 | S-1 (registration) | MAXCYTE, INC. | 0001104659-21-090682 ↗ |
| 2021-07-26 | S-1/A | S-1/A (amendment) | MAXCYTE, INC. | 0001104659-21-095556 ↗ |
| 2021-07-29 | S-1MEF | S-1MEF (added securities) | MAXCYTE, INC. | 0001104659-21-097793 ↗ |
| 2021-07-29 | EFFECT | EFFECT (declared effective) | MAXCYTE, INC. | 9999999995-21-002983 ↗ |
| 2021-07-30 | 424B4 | 424B4 (final prospectus) | MAXCYTE, INC. | 0001104659-21-098238 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-07-26 | S-1/A | registration statement | $11.50–$13.50 | 12,000,000 | - | Nasdaq MXCT | 5 | primary document; range, shares headline, cover names 5 | document ↗ | |
| 2021-07-30 | 424B4 | final prospectus | $13.00 | 13,500,000 | $175,500,000 | Nasdaq MXCT | 5 | primary document; price sentence, shares headline, proceeds table, underwriting table 5, cover names 5 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Al-Wakeel Yasir B. | Director | 8 | 2021–2026 | ||
| Brooke William W | Director | 8 | 2021–2026 | ||
| Doerfler Douglas | Director,Officer | President and CEO | 15 | 2021–2023 | |
| DOUGLAS RICHARD | Director | 10 | 2021–2026 | ||
| Erck Stanley C | Director | 11 | 2021–2026 | person page Fuzzy | |
| Hemrajani Rekha | Director | 9 | 2021–2026 | ||
| Holtz Ron | Officer | Chief Financial Officer; SVP and CAO | 5 | 2021–2023 | |
| Johnston John Joseph | Director | 24 | 2021–2026 | ||
| Mandell Art | Director | 5 | 2021–2024 | ||
| Masoud Maher | Director,Officer; Officer | EVP and General Counsel; President and CEO | 10 | 2021–2026 | |
| Murphy Amanda Louise | Officer | Chief Financial Officer | 4 | 2021–2022 | |
| Ross Thomas M. | Officer | EVP, Global Sales; EVP, GLOBAL SALES; EVP, Global Sales & Marketing; EVP, GLOBAL SALES & MARKETING | 17 | 2021–2024 | |
| THOMPSON J STARK PHD | Director | 2 | 2021 | ||
| Casdin Capital, LLC | TenPercentOwner | 4 | 2021–2022 | ||
| Casdin Eli | TenPercentOwner | 4 | 2021–2022 | ||
| Casdin Partners GP, LLC | TenPercentOwner | 4 | 2021–2022 | ||
| Casdin Partners Master Fund, L.P. | TenPercentOwner | 4 | 2021–2022 | ||
| Sumen Cenk | Officer | Chief Scientific Officer | 2 | 2022–2023 | |
| BALTHROP PATRICK J | Director | 6 | 2022–2026 | ||
| Swirsky Douglas J | Officer | Chief Financial Officer; CHIEF FINANCIAL OFFICER | 7 | 2023–2026 | |
| Sandoval David I. | Officer | General Counsel; GENERAL COUNSEL | 5 | 2024–2025 | |
| Soleymannezhad Ali | Officer | Chief Commercial Officer | 4 | 2024–2025 | |
| Collins Cynthia | Director | 4 | 2024–2026 | ||
| Ahuja Parmeet | Officer | Chief Financial Officer | 3 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2016-09-29 | MAXCYTE, INC. | Biotechnology | $760,308 | $760,308 | 9 | 1 |
| 2014-12-16 | MAXCYTE, INC. | Biotechnology | $1,700,000 | $1,700,000 | 21 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | MAXCYTE, INC. | MD | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | MAXCYTE, INC. | MD | Form D private offerings | CIK (EXACT) |
| SEC filer | MAXCYTE, INC. | SEC filers (EDGAR) | CIK (EXACT) | |
| Business registration | MAXCYTE, INC | State business registries | name and state | |
| Form 5500 plan sponsor | MAXCYTE, INC. | EIN (EXACT) | ||
| Federal award recipient | MAXCYTE, INC. | Federal spending (USAspending) | name and state | |
| Person page | Stanley C Erck | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Services-Commercial Physical & Biological Research, MD first:
- BIORELIANCE CORP MD
- SCICORPS INC MD
- COMBICHEM INC CA
- AURORA BIOSCIENCES CORP CA
- DGI RESOLUTION INC K6
- PRA INTERNATIONAL INC VA
- QUEST DIAGNOSTICS INVESTMENTS INC NJ
- SIGNAL PHARMACEUTICALS INC CA
- CURAGEN CORP MA
- DELTAGEN INC CA
In other datasets, the same topic (Medical research) in MD:
- Form D issuer: 20/20 GeneSystems, Inc. (Form D private offerings)
- Nonprofit: AAHBB RESEARCH INSTITUTE INC (Nonprofits (IRS Form 990))
Interests: Services-Commercial Physical & Biological Research · Medical research